<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504944</url>
  </required_header>
  <id_info>
    <org_study_id>DROP-ROP-0.2%</org_study_id>
    <nct_id>NCT02504944</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)</brief_title>
  <official_title>Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Newborn With Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Meyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Meyer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye
      drops in treating preterm newborns with a precocious stage of retinopathy of prematurity
      (ROP). Preterm newborns (gestational age 23-32 weeks) with a stage 1 ROP will receive
      propranolol 0.2% eye drops treatment until retinal vascularization will be completed, but no
      more than 90 days.

      Propranolol concentrations will be measured on dried blood spots at the steady state (10th
      day). Cardiovascular and respiratory parameters will be continuously monitored. Blood
      samplings checking metabolic, renal and liver functions will be performed periodically, as
      well as cardiac function, in order to verify the treatment safety. Serial ophthalmological
      evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and
      the possible complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of progression from stage 1 ROP to zone II stage 2 ROP with plus</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of progression from stage 1 ROP to zone II stage 3 ROP with plus</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of propranolol at the steady state measured by dried blood spots</measure>
    <time_frame>10th day of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of newborns who progress to Stage 2 without plus ROP</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns who progress to Stage 3 without plus ROP</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns who progress to Stage 4 with total or partial retinal detachment</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns who progress to Stage 5 ROP with total or partial retinal detachment</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns who need vitrectomy</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of adverse events due to eye drop propranolol treatment</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Propranolol 0.2% eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol 0.2% eye drops</intervention_name>
    <description>Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.</description>
    <arm_group_label>Propranolol 0.2% eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm newborns (gestational age 23-32 weeks) with stage 1 ROP

          -  A signed parental informed consent

        Exclusion Criteria:

          -  Newborns with heart failure

          -  Newborns with recurrent bradycardia (heart rate &lt; 90 beat per minute)

          -  Newborns with second or third degree atrioventricular block

          -  Newborns with congenital cardiovascular anomalies, except for persistent ductus
             arteriosus, patent foramen ovale and small ventricular septal defects

          -  Newborns with hypotension

          -  Newborns with renal failure

          -  Newborns with actual cerebral haemorrhage

          -  Newborns with other diseases which contraindicate the use of beta-adrenoreceptor
             blockers.

          -  Newborns with a more severe stage of ROP than stage 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Filippi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A. Meyer University Childrens' Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Filippi, MD</last_name>
    <phone>+39-055-5662434</phone>
    <email>l.filippi@meyer.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Aversa, MD</last_name>
      <email>aversalvo@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Graziella Iacono, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Neascimbeni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabina Bettelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, A. Meyer University Childrens' Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Filippi, MD</last_name>
      <phone>+39-055 5662434</phone>
      <email>l.filippi@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Luca Filippi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Pediatrics and Neonatology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giacomo Cavallaro, MD</last_name>
      <email>giacomo.cavallaro@mangiagalli.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo Cavallaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Bozzetti, MD</last_name>
      <email>vbozzetti@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Tomasini, MD</last_name>
      <email>b.tomasini@ao-siena.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Bossi, MD</last_name>
      <email>angela.bossi@ospedale.varese.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Padrini L, Isacchi B, Bilia AR, Pini A, Lanzi C, Masini E, Della Bona ML, Calvani AM, Ceccantini R, la Marca G, Filippi L. Pharmacokinetics and local safety profile of propranolol eye drops in rabbits. Pediatr Res. 2014 Oct;76(4):378-85. doi: 10.1038/pr.2014.108. Epub 2014 Jul 16.</citation>
    <PMID>25029260</PMID>
  </reference>
  <reference>
    <citation>Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G, Tinelli F, Araimo G, Cristofori G, la Marca G, Della Bona ML, La Torre A, Fortunato P, Furlanetto S, Osnaghi S, Mosca F. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013 Dec;163(6):1570-1577.e6. doi: 10.1016/j.jpeds.2013.07.049. Epub 2013 Sep 18.</citation>
    <PMID>24054431</PMID>
  </reference>
  <reference>
    <citation>Dal Monte M, Casini G, la Marca G, Isacchi B, Filippi L, Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Eye Res. 2013 Jun;111:27-35. doi: 10.1016/j.exer.2013.03.013. Epub 2013 Mar 23.</citation>
    <PMID>23528535</PMID>
  </reference>
  <reference>
    <citation>Filippi L, Cavallaro G, Fiorini P, Malvagia S, Della Bona ML, Giocaliere E, Bagnoli P, Dal Monte M, Mosca F, Donzelli G, la Marca G. Propranolol concentrations after oral administration in term and preterm neonates. J Matern Fetal Neonatal Med. 2013 May;26(8):833-40. doi: 10.3109/14767058.2012.755169. Epub 2013 Jan 31.</citation>
    <PMID>23205867</PMID>
  </reference>
  <reference>
    <citation>Della Bona ML, Malvagia S, Villanelli F, Giocaliere E, Ombrone D, Funghini S, Filippi L, Cavallaro G, Bagnoli P, Guerrini R, la Marca G. A rapid liquid chromatography tandem mass spectrometry-based method for measuring propranolol on dried blood spots. J Pharm Biomed Anal. 2013 May 5;78-79:34-8. doi: 10.1016/j.jpba.2013.01.034. Epub 2013 Feb 4.</citation>
    <PMID>23434527</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Meyer</investigator_affiliation>
    <investigator_full_name>Luca Filippi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Retinopathy of prematurity</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Newborn</keyword>
  <keyword>Eye Drops</keyword>
  <keyword>Retinal angiogenesis</keyword>
  <keyword>Retinal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

